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Abstract
Background: Epitope vaccines have been suggested as a strategy to counteract viral escape and development of
drug resistance. Multiple studies have shown that Cytotoxic T-Lymphocyte (CTL) and T-Helper (Th) epitopes can
generate strong immune responses in Human Immunodeficiency Virus (HIV-1). However, not much is known about
the relationship among different types of HIV epitopes, particularly those epitopes that can be considered potential
candidates for inclusion in the multi-epitope vaccines.
Results: In this study we used association rule mining to examine relationship between different types of epitopes
(CTL, Th and antibody epitopes) from nine protein-coding HIV-1 genes to identify strong associations as potent
multi-epitope vaccine candidates. Our results revealed 137 association rules that were consistently present in the
majority of reference and non-reference HIV-1 genomes and included epitopes of two different types (CTL and Th)
from three different genes (Gag, Pol and Nef). These rules involved 14 non-overlapping epitope regions that
frequently co-occurred despite high mutation and recombination rates, including in genomes of circulating
recombinant forms. These epitope regions were also highly conserved at both the amino acid and nucleotide
levels indicating strong purifying selection driven by functional and/or structural constraints and hence, the
diminished likelihood of successful escape mutations.
Conclusions: Our results provide a comprehensive systematic survey of CTL, Th and Ab epitopes that are both
highly conserved and co-occur together among all subtypes of HIV-1, including circulating recombinant forms.
Several co-occurring epitope combinations were identified as potent candidates for inclusion in multi-epitope
vaccines, including epitopes that are immuno-responsive to different arms of the host immune machinery and can
enable stronger and more efficient immune responses, similar to responses achieved with adjuvant therapies.
Signature of strong purifying selection acting at the nucleotide level of the associated epitopes indicates that these
regions are functionally critical, although the exact reasons behind such sequence conservation remain to be
elucidated.
Background
Human Immunodeficiency Virus (HIV), the virus
responsible for Acquired Immunodeficiency Syndrome
(AIDS), is one of the major causes of death around the
world today. There were 2.1 million AIDS related deaths
and 2.5 million new infections in 2007 alone with over
33.2 million people living with HIV-1 infection (AIDS
epidemic update 2007, UNAIDS). Although the use of
the Highly Active Anti-Retroviral Therapy (HAART)
has significantly reduced the mortality and morbidity of
HIV patients by chronically suppressing HIV-1 replica-
t i o n ,w ea r ef a rf r o mf i n d i n gac u r e[ 1 , 2 ] .M o r e o v e r ,
drug regimens not only come with many drawbacks
such as increased malignancies, insulin resistance, glu-
cose intolerance and diabetes mellitus [3,4]. Other chal-
lenges to HAART efficiency are development of latency
and drug resistance as viruses mutate and escape from
the drug action [5-8]. Despite isolated stories about
cures for HIV infection [9] and a recent modest success
in a clinical vaccine trial [10,11], a vaccine that can give * Correspondence: opiontki@kent.edu
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remain to be designed [12,13].
Immune response to the HIV infection consists of a
combination of both humoral and cellular immunity
[14,15]. Furthermore, different immune responses can
target the same regions of viral peptides. For example,
V3-loop peptides of the Env gene can be presented by
both class I and class II major histocompatibility com-
plex (MHC) molecules and can be recognized by both
Cytotoxic T-Lymphocytes (CTLs) and T-Helper cells
(Th), as well as by neutralizing antibodies (Ab) (e.g.,
[16-18]). Likewise, a highly conserved region in the Gag
gene (287-309 amino acid residues in p24) has been
shown to interact with CTL, as well as B and T-Helper
cells [19]. This, in turn, implies that escape changes dri-
ven by the selection pressure from one type of the host
immune response can also lead to escape from a differ-
ent immune mechanism (e.g., [20]). Recently, epitope
vaccines (vaccines that contain synthetic peptides repre-
senting epitopes from pathogens) against HIV as well as
other viruses such as Influenza have been suggested as a
new strategy to avoid the viral escape from the host
immune system as well as to counteract development
of resistance against drugs [21-24]. While recognition of
epitopes by the host immune system and mounting of
immune response against pathogen is important in con-
trolling and prevention of infections [25], mutations in
the epitope regions can help pathogens to evade recog-
nition by immune receptors and lead to subsequent
escape of host immune system [26-28]. Selection by the
immune system that promotes amino acid sequence
diversification at viral epitopes has been shown to play a
significant role in the evolution of different viruses,
including HIV-1, SIV, Hepatitis C virus, and the Influ-
enza A virus (e.g., [29-32]).
Based on the type of recognizing receptors, there are
three types of epitopes, namely CTL/CD8
+ epitopes
(CTL), T-Helper/CD4
+ epitopes (Th) and neutralizing
antibody (Ab) epitopes. Single and multi-epitope vac-
cines containing CTL, Th and Ab epitopes have been
described [33,34]. Inclusion of highly conserved epitopes
from different genomic regions in a multi-epitope vac-
cine has been suggested as a strategy to induce a
broader cellular immune response that targets the
majority of the virus variants [33,35,36]. However, iden-
tification of good vaccine candidates based on the extent
of sequence conservation in HIV is a challenging pro-
blem, compounded by the fast mutation [37,38] and
recombination rates [39-41], overlapping reading frames
[42] and overall high degree of sequence divergence
among the global HIV-1 population [43].
Recently, we reported a series of highly conserved,
co-occurring CTL epitopes from three different genes
(Gag, Pol and Nef) that are frequently found in
association with each other and therefore can be consid-
ered strong candidates for inclusion in CTL multi-
epitope vaccines [44]. However, to further improve the
vaccine efficiency, the use of adjuvants capable of indu-
cing a strong cellular response and potentially augment-
ing these responses should be considered (e.g., [45-48]),
including use of multiple types of epitopes [49]. For
example, Gram et al. (2009) [49] recently showed that
while the use of immune-stimulating adjuvant CAF01
induces strong a CTL response, inclusion of a CD4
T-Helper epitope further improves this CTL response.
Thus, this study was focused on identifying strong
associations between different types of epitopes from
multiple genes in search of potent multi-epitope vaccine
candidates. Our results identified several highly con-
served T-Helper epitopes that frequently co-occur with
particular highly conserved CTL epitopes and that these
epitopes co-occur in the majority of HIV-1 genomes of
different subtypes and groups as well as circulating
recombinant forms. Here we report 137 unique CTL
and T-Helper epitope associations (also referred to as
association rules) that involve epitopes from 14 non-
overlapping genomic regions from three different genes,
namely, Gag, Pol and Nef. Widespread presence of these
epitope combinations across highly divergent HIV-1
genomes sampled worldwide, including circulating
recombinant forms, coupled with a high degree of evo-
lutionary sequence conservation likely reflective of sub-
stantial fitness impacts of escape mutations [50] makes
them potent candidates for a multi-epitope vaccine.
Methods
HIV-1 genomic sequence data and sequence alignment
HIV-1 sequences in the primary analysis included
90 HIV-1 reference sequences from the 2007 subtype
reference set of the HIV Sequence database (Los Alamos
National Laboratory (LANL), http://www.hiv.lanl.gov),
which included full length genomes containing sequences
from all nine protein-coding genes, one sequence per
patient (List of sequences, including GenBank accession
numbers, is described in the Additional file 1). Amino
acid and nucleotide sequence alignments were collected
separately for analyses of epitope presence and estima-
tion of nucleotide substitution rates, respectively. These
curated alignments were generated using HMMER and
verified manually (HIV sequence database by LANL).
Further details about sequence alignments and selection
of reference sequences are available in the HIV Sequence
Database and Leitner et al. (2005) [51], respectively. This
reference set was comprised of 47 non-recombinant
sequences, including 40 sequences from M group (repre-
s e n t i n gs u b t y p e sA 1 ,A 2 ,B ,C ,D ,F 1 ,F 2 ,G ,H ,J ,a n dK ) ,
7 sequences from N and O groups and 43 recombinant
sequences, with approximately 4 representatives for each
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because it roughly approximates the diversity of each
subtype as represented in the database. Inclusion of
circulating recombinant forms (CRFs) that are defined as
inter-subtype recombinant viruses identified from more
than a single patient and spreading epidemically [52,53],
allowed us to capture those highly conserved epitopes
that are shared with non-recombinant genomes and are
also present in the majority of the recombinant reference
genomes.
HIV-1 Epitopes
The sets of CTL, T-Helper and antibody epitopes were
collected from the HIV Immunology database (Los Ala-
mos National Laboratory, http://www.hiv.lanl.gov/content/
immunology) [54], the most comprehensive curated
source of known HIV epitopes [55]. A total of 606 linear
epitopes were collected, including 229 CTL epitopes that
were described as the “best defined” CTL epitopes and
were supported by strong experimental evidence, as
defined by Frahm et al., 2007 [56], 296 T-Helper epitopes
and 81 antibody epitopes (Table 2, Additional file 2).
Because of the challenges in identifying primary sequence
elements of structurally conserved discontiguous confor-
mational epitopes (e.g., [57,58]), conformational epitopes
were not included in the study. Only the epitopes proven
to be immunogenic in human as per the HIV Immunology
database were used in this study. The overview of epitope
mapping techniques and challenges in epitope identifica-
tion has been described elsewhere [59,60]. Although CTL
and Th epitopes had representation from all nine protein-
coding genes, Ab epitopes were absent in the Vif, Vpr, Rev
and Vpu genes. The majority of the Ab epitopes (75 out of
81) belonged to the Env gene, while the Pol gene had
three and the Gag, Tat and Nef genes had one epitope
each [61-65]. It should be noted that because of the high
amino acid sequence diversity of the Env gene that may
differ by as much as 30% between subtypes [43], very few
antibody epitopes if at all could be expected to be con-
served across a broad range of HIV-1 sequences; thus,
in this study we primarily focus on CTL and T-Helper
epitopes. Restricting HLA allele(s) for associated epitopes
are given in Table 3 as per HIV Immunology database and
IEDB http://www.immuneepitope.org/.
Inclusion of epitopes in association-rule mining
In order to identify the most broadly represented epi-
topes, each epitope sequence was aligned with 90 refer-
ence sequences and the epitopes present in more than
75% of the reference sequences (i.e., perfect amino acid
sequence match in more than 67 sequences) were
selected for association rule mining. A total of 47 epi-
t o p e s ,i n c l u d i n g3 3C T L ,1 2T - H e l p e ra n d2a n t i b o d y
epitopes, were present in more than 75% of the reference
Table 1 Overview of HIV-1 sequences used in the analyses
Type of genome Group Subtype Reference sequences
# Non-reference sequences* Total (Global HIV-1 population
^)
Non - recombinant M group A - 6 6
A1 4 46 50
A2 3 - 3
B 5 158 163
C 4 350 354
D 4 32 36
F1 4 6 10
F2 4 - 4
G 4 12 16
H3 - 3
J3 -3
K2 - 2
M - Total 40 610 650
N group 3 2 5
O group 4 13 17
N & O Total 7 15 22
Non-recombinants - Total 47 625 672
Circulating Recombinant Forms (CRF) 43 263 306
Total 90 888 978
The table shows numbers of HIV-1 sequences of different subtypes among reference sequences and global population used in the analyses.
# Reference sequences used in the primary analyses to identify association rules
* Non-reference sequences were collected from 2008 Web alignment of HIV Sequence database
^ Total number of sequences in the global HIV-1 population used in the analysis
Paul and Piontkivska BMC Microbiology 2010, 10:212
http://www.biomedcentral.com/1471-2180/10/212
Page 3 of 16sequences. Among them one CTL and two Th epitopes
were completely overlapping with other epitopes of the
same type without amino acid differences and, thus, were
excluded from the association rule mining to avoid
redundancy (e.g., the CTL epitope from the Gag gene
VIPMFSAL overlaps with the CTL epitope EVIPMFSAL
and is present in exactly the same reference sequences).
Epitopes of different types that completely overlap with
each other without amino acid differences were also
included to take into account multi-functional regions
(e.g., the CTL epitope KTAVQMAVF completely over-
laps with the Th epitope LKTAVQMAVFIHNFK without
amino acid differences). The final set of epitopes con-
sisted of 44 epitopes representing 4 genes, namely, Gag,
Pol, Env and Nef, and included 32 CTL, 10 Th and 2 Ab
epitopes (17 epitopes from Gag, 22 from Pol,2f r o mEnv
and 3 from Nef) (Table 2).
Identification of associated epitopes
To identify frequently co-occurring epitopes of different
types, we used association rule mining, a data mining
technique that identifies and describes relationships
(also referred to as associations or association rules)
among items within a data set [66]. Although associa-
tion rule mining is most often used in marketing ana-
lyses, such as “market basket” analysis [67,68], this
technique has been successfully applied to several biolo-
gical problems (e.g., [69-71]), including discovery of
highly conserved CTL epitopes [44].
T h ed a t ao np r e s e n c ea n da b s e n c eo fs e l e c t e d4 4e p i -
topes in 90 reference sequences (as described above)
w a su s e da st h ei n p u tf o rt h eA p r i o r ia l g o r i t h m[ 6 7 ]
implemented in the program WEKA [66,72]. Because of
our focus on the highly conserved epitope associations,
the minimum support was set at 0.75 to include only
association rules present in at least 75% of the reference
sequences. The confidence was set very high at 0.95 to
generate only very strong associations, i.e., where epi-
topes co-occur in more than 95% of the sequences, and
all generated association rules were exhaustively enum-
erated and examined. The maximum number of rules
identified was set at 100000 to ensure that all associa-
tion rules above the support and confidence thresholds
are captured. Once identified, association rules that
involved the same epitopes, but in different order, were
“collapsed” into a single “unique” rule (i.e., A occurs
with B and B occurs with A are considered the same
“unique” rule) [44].
Epitope-associations in a worldwide set of HIV-1 genomes
To verify whether the association rules identified using a
representative reference set reflect associations existing
Table 2 Overview of epitopes used in the analyses
Gene Protein Total no. of epitopes Highly conserved epitopes* No of associated epitopes
^
CTL
# Th Ab Total CTL Th Ab Total CTL Th Ab Total
Gag p17 18 32 - 50 1 - - 1 - - - -
p24 42 88 1 131 8 6 - 14 8 6 - 14
p2p7p1p6 6 18 - 24 2 - - 2 2 - - 2
Total 66 138 1 205 11 6 - 17 10 6 0 16
Pol Gag-Pol 1 - - 1 - - - - - - - -
Protease 8 - - 8 1 - - 1 1 - - 1
RT 39 20 3 62 12 1 - 13 12 1 - 13
RT-
Integrase 1 1 - 2 1 - - 1 1 - - 1
Integrase 12 11 - 23 5 2 - 7 4 2 - 6
Total 61 32 3 96 19 3 22 18 3 0 21
Vif 9 2 - 11 - - - - - - - -
Vpr 76- 1 3 - - - - - - - -
Tat 46 1 1 1 - - - - - - - -
Rev 45- 9 - - - - - - - -
Vpu 11- 2 - - - - - - - -
Env 40 82 75 197 - - 2 2 - - 1 1
Nef 37 24 1 62 2 1 - 3 2 1 - 3
Total 229 296 81 606 32 10 2 44 30 10 1 41
# CTL epitopes included only the best-defined epitopes as described by Frahm et al. (2007) [56]
* Only those epitopes present in more than 75% of the reference sequences were considered as highly conserved and thus included in the association rule
mining. 3 epitopes completely overlapping with other epitopes of same type without amino acid differences were not included.
^ Associated epitopes are epitopes involved in association rules identified with a support value of 0.75 and confidence value of 0.95
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Page 6 of 16in a worldwide HIV-1 population, we examined a larger
set of 978 HIV-1 sequences. This genome set included
888 HIV-1 sequences from the 2008 web alignment of
the HIV Sequence database selected to include full-
length Gag, Pol and Nef genes for each genome, as well
as 90 reference sequences used in the first steps of the
analysis. The larger genome set included 650 sequences
from the M group, 22 from the N and O groups and
306 recombinant sequences (Table 1, Additional file 3).
An epitope-association was considered to be present in
a particular genome only if all the epitopes participat-
ing in that association rule were present without any
amino acid differences.
Estimation of the nucleotide substitution rates
To assess the extent of sequence divergence of asso-
ciated epitopes, the number of synonymous nucleotide
substitutions per synonymous site (dS) and the num-
ber of nonsynonymous nucleotide substitutions per
nonsynonymous site (dN) were estimated in 90 HIV-1
reference sequences. Each codon was classified as (i)
non-epitope or as epitope region, if the codon was
mapped to at least one type of epitope. The epitope
regions were further subdivided into (ii) associated
epitopes (i.e., epitopes participating in association
rules), (iii) non-associated epitopes (i.e., those epitopes
that were sufficiently conserved to be included in
association rule mining but were not participating in
association rules), and (iv) all other, variable, epitopes
that were excluded from the association rule mining
(i.e., those absent from more than 25% of sequences).
Pairwise dN and dS values were estimated using the
Nei-Gojobori method with the Jukes-Cantor correc-
tion [73]. This simple method was chosen because it
is expected to have lower variance than more compli-
cated substitution models [74]. The MEGA4 program
[75] was used, and the standard errors were estimated
with 500 bootstrap replications.
Results
Discovery of epitope associations in 90 HIV-1 reference
sequences
Out of 606 epitopes included in the initial analyses, a
total of 44 epitope regions, including 32 CTL, 10 Th
and 2 Ab epitopes, were present (as a perfect amino
acid sequence match) in at least 75% of the 90 HIV-1
reference sequences and thus were included in the
association rule mining. Using a high confidence value
of 95% allowed us to focus only on the strongest asso-
ciation rules that involve the most frequently co-occur-
ring epitopes. Using this stringent confidence cut-off, a
total of 60626 associations involving three types of epi-
topes belonging to four genes, Gag, Pol, Env and Nef,
were discovered, of them 6142 association rules were
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Page 7 of 16unique combinations of epitopes (Table 4). A total of 41
epitopes that belonged to 27 non-overlapping genomic
regions from four genes were found to be involved in
these association rules (Table 3). Figure 1 shows an
example of an association rule involving four epitopes of
two types (CTL and Th) and three genes (Gag, Pol and
Nef).
The majority of the unique epitope association rules
(cumulatively comprising > 80% of all rules) involved
o n l yt h r e et of i v ee p i t o p e s ,w i t ht h el a r g e s tc a t e g o r y
comprised of rules with four epitopes (2098 associa-
tions), followed by 1719 associations with five and 1145
associations with three epitopes, respectively (Figure 2,
Table 4). Notably, a significant number of association
rules involved 6 to 8 epitopes (793 associations with six,
216 with seven and 31 with 8 epitopes, respectively).
There were only two association rules in which 9 epi-
topes were involved. More details on number of associa-
tions based on epitope type and genes involved are
given in Additional file 4. When gene locations were
considered, over 82% of the unique epitope associations
included epitopes from both the Gag and Pol genes, fol-
lowed by 5.9% and 6.1% of associations involving only
the Gag and only Pol genes, respectively. Another 5.4%
of unique association rules involved epitopes from the
Nef gene, of which almost 60% of rules involved three
genes, Gag, Pol and Nef, with the remainder distributed
mostly between Gag-Nef and Pol-Nef associations
(approximately 24% and 16%, respectively). There were
only five association rules that involved epitopes from
the Env gene. Four of these five were from Gag-Env and
one from Pol-Env associations. Notably, associations
with antibody epitopes were limited to these five Env
association rules, which can partially be attributed to
the high degree of sequence divergence among the Env
sequences that can differ by as much as 30% at the
amino acid level [76].
No association rules included all three types of epi-
topes (CTL, Th and Ab) and four genes (Gag, Pol, Env
and Nef). However, several “multi-type” association rules
comprised of two different epitope types (CTL and Th)
and three genes (Gag, Pol and Nef) were discovered
(Figure 1, Additional file 5). For example, in the associa-
tion rule: GHQAAMQML (CTL, Gag)-P K E P F R D Y V
(Th, Gag)-K L N W A S Q I Y( C T L ,Pol) - FLKEKGGL
(CTL, Nef) (Figure 1), GHQAAMQML, KLNWASQIY
and FLKEKGGL are CTL epitopes from the Gag, Pol
and Nef genes, respectively, while PKEPFRDYV is a Th
epitope from the Gag g e n e .O v e r a l l ,t h e r ew e r e1 3 7
“multi-type” associations involving epitopes from two
types and three genes (2T-3G) among a total of 21 CTL
and Th epitopes from the Gag, Pol and Nef genes (Addi-
tional file 5). These 21 epitopes can be mapped to 14
different non-overlapping genomic regions (Table 3)
and a single association rule is generally spread across 3
to 5 of such regions. Interestingly, even though the asso-
ciation rule with the maximum number of epitopes in a
single rule (9 epitopes) involved four non-overlapping
genomic regions, it included epitopes from only two
genes, Gag and Pol.
Epitope-associations in the reference genome are
representative of the global HIV-1 population
Presence of association rules discovered in the reference
genome set was verified by analyzing a larger worldwide
set of 978 HIV-1 genomes (including 888 sequences
from the 2008 web alignment and 90 reference
sequences from the HIV Sequence database). The Gag,
Pol and Nef genes in each sequence were concatenated
for the purpose of the analysis, and presence of each
association rule (as a complete match of all epitope
regions involved) was noted. The results showed that
most of the epitope-associations were present in the
majority of genomes from the global HIV-1 population.
In particular, out of 137 epitope associations involving
two different types and three different genes (2T-3G),
134 association rules were present in more than 70% of
the HIV-1 genomes (i.e., in > 685 sequences)
Table 4 Distribution of unique association rules according to genes involved in each association rule
Gag only Pol only Nef only Gag-Pol Gag-Env Gag-Nef Pol-Env Pol-Nef Gag-Pol-Nef Total*
Association rules with 2 epitopes 46 24 1 55 3 5 1 3 0 138
Association rules with 3 epitopes 104 160 0 768 1 33 0 23 56 1145
Association rules with 4 epitopes 108 135 0 1699 0 29 0 23 104 2098
Association rules with 5 epitopes 73 47 0 1551 0 11 0 4 33 1719
Association rules with 6 epitopes 29 6 0 753 0 2 0 0 3 793
Association rules with 7 epitopes 5 0 0 211 0 0 0 0 0 216
Association rules with 8 epitopes 0 0 0 31 0 0 0 0 0 31
Association rules with 9 epitopes 0 0 0 2 0 0 0 0 0 2
Total 365 372 1 5070 4 80 1 53 196 6142
* There were no epitope associations in the following categories: Env only, Nef-Env, Gag-Pol-Env, Gag-Nef-Env, Pol-Nef-Env, Gag-Pol-Env-Nef
$ Detailed break-up of number of associations based on epitope type and genes involved is given in additional file 4
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Page 8 of 16(Additional file 6). Further, 978 sequences were also
analyzed for the presence/absence of 21 individual epi-
topes participating in the 2T-3G associations. The
results revealed that with the exception of a single CTL
epitope (VPRRKAKII from the Pol gene, present in 65%
of the sequences), all other epitopes were present in
over 85% of the sequences (Additional file 7).
These results underscore the importance of these 21
highly conserved epitope regions, as reflected by their
substantial presence across the global population of
HIV-1. Notably, similar pattern of presence with high
frequency was observed when the sets of M group
sequences (610), as well as sets of recombinant
sequences (263), were considered separately. Interest-
ingly, the latter group had these epitopes present in at
least 80% of all sequences. On the other hand, only 7
out of the 21 epitopes were present in more than 75%
of the sequences when the N and O groups were con-
sidered separately, which may reflect both the high
degree of sequence divergence between N, O and M
groups [43,77], as well as that the majority of epitopes
used here were discovered in M group sequences (HIV
Molecular Immunology database, http://www.hiv.lanl.
gov/content/immunology.
Associated epitope regions are highly conserved at both
amino acid and nucleotide levels
To delineate selective forces affecting the evolution of dif-
ferent genomic regions in HIV-1 genomes, particularly
those influencing epitope regions, the number of synon-
ymous substitutions per synonymous site (dS) and the
number of nonsynonymous (amino acid altering) substitu-
tions per nonsynonymous site (dN) were estimated in all
pairwise sequence comparisons of 90 reference genomes.
Each codon was classified into one of four categories,
either as (i) non-epitope, or as (ii) associated, (iii) non-
associated or (iv) variable epitope regions (see Methods
section for details). Overall, in all pairwise sequence com-
parisons and different categories of epitope regions the
number of synonymous substitutions per synonymous site
significantly exceeded the number of nonsynonymous sub-
stitutions per nonsynonymous site, i.e., dS >> dN (paired
t-test, p < 0.001) (Table 5). This indicates that purifying
Figure 2 Relative composition of unique association rules
involving multiple genes (Gag, Pol and Nef) and epitope types
(Cytotoxic T Lymphocyte (CTL), T-Helper (Th) and antibody
(Ab) epitopes). The 6142 unique association rules are classified
according to the genes that harbor these epitopes. The pie-chart
inside each segment represents the division according to the
epitope region types involved. The single association rule in Nef-
only category involved CTL and Th epitopes, while that in Pol-Env
category involved CTL and Ab epitopes. Out of four association
rules involving epitopes from Gag and Env, three belonged to
CTL-Ab and one belonged to Th-Ab epitope regions types.
Figure 1 A “multi-type” association rule involving three CTL and one Th epitope from three different genes, Gag, Pol and Nef in
reference to HIV-1 genome. The corresponding amino acid coordinates (as per HIV-1 HXB2 reference sequence) and HLA allele supertypes
recognizing these epitopes are also shown.
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Page 9 of 16selection plays a significant role in the evolution of HIV
including evolution of the epitope regions, which is in
agreement with our previous results [44,78,79]. Similar
trend of overall dS >> dN (paired t-test, p < 0.001) was
also observed when sequences of the N and O groups
were considered separately. However, because of the high
degree of sequence divergence between the three groups
due to their independent origin via separate cross-species
transmission events [80-82], we will focus our discussion
on the pairwise comparisons of the M group sequences
only (including CRFs).
The average dN and dS values for each category of
sites obtained from the pairwise comparisons of the
reference sequences from the M group are shown in
Table 5. Notably, associated epitopes have significantly
smaller dN and dS values than respective dN and dS
values at other categories of sites, including non-
epitopes (one-way ANOVA and nonparametric Kruskal-
Wallis tests, p < 0.001) (see also Additional file 8).
While significantly lower dN values at associated epi-
topes can be attributed to strong purifying selection
operating to reduce amino acid diversity at these highly
conserved epitope regions, in agreement with our pre-
vious results [44,78], the significantly lower dS values
indicate that the high degree of sequence conservation
exist not only at the amino acid level, but also at the
nucleotide level in these associated regions. Notably,
when we consider correlations between the levels of
synonymous and nonsynonymous sequence divergence
from different site categories for the same pair of
sequences, relatively strong and statistically significant
positive correlations (Pearson correlation coefficient
values between 0.67 and 0.77, p < 0.01) exist between
dN and dS values for both non-epitope and epitope
regions that were not included in the association rule
mining, including variable epitopes, but not for asso-
ciated epitopes. Similar trends are detected using non-
parametric correlation (Kendall’s tau values between
0.34 and 0.45, p < 0.001). This may be attributed to
common factors (such as functional and structural
constraints and mutation rate) influencing evolution of
these regions, so that the regions with higher dS values
are also likely to have higher dN values. On the other
hand, the levels of synonymous and nonsynonymous
sequence divergence at the associated epitopes have
only weak or non-significant correlation both with each
other (r = -0.14, p < 0.01), as well as with dN and dS
values at other regions within the same genomes (see
Additional file 9). These results indicate that the lower
dS values at the associated epitope regions are
not merely the reflection of the overall lower mutation
rates, but rather due to specific selective forces preser-
ving nucleotide sequences in these regions, much like
purifying selection operating to maintain amino acid
sequences at the same epitopes. Although the exact nat-
ure of these selection constraints remains to be eluci-
dated, it may be related with the structural constraints
at the level of RNA structure, including potential regula-
tory RNA elements that are yet to be described in the
HIV genome [83]. Interestingly, when the number of
sites characterized as “structured” and “non-structured”
in Watts et al. (2009) [83] study was compared among
regions classified as associated epitopes and non-
epitopes in this study, the results showed that associated
epitope regions tend to harbor a significantly larger pro-
portion of structured than non-structured sites while
non-epitopes harbor more non-structured than struc-
tured sites (Fisher’s exact test, p < 0.05). Because struc-
tured regions are expected to be more evolutionary
conserved at the nucleotide level to preserve the ability
to form secondary or higher-order RNA structures, this
is consistent with the overall lower degree of sequence
divergence observed among associated epitopes. How-
ever, no statistically significant difference was observed
when the numbers of structured and unstructured sites
were compared between associated epitopes and epitope
regions not included in the association rule mining
(p > 0.05). This can be attributed to a variety of factors,
including that the latter epitope category is a heteroge-
neous mixture of epitopes that are evolving with differ-
ent rates under different selection pressures [78,79].
Likewise, as pointed out by Watts et al. (2009) [83],
while most structures in their studied HIV-1 model
have been well characterized, some structural RNA ele-
ments may still require further refinement.
Discussion
Overall, our results identified a set of strong associations
between CTL and T-Helper epitopes that co-occur in
t h em a j o r i t yo ft h eH I V - 1g e n o m e sw o r l d w i d ea n dc a n
be considered strong candidates for multi-epitope vac-
cine and/or treatment targets. There have been several
attempts to design multi-epitope vaccines using different
Table 5 Nucleotide substitution rates among different
epitope and non-epitope regions
dN SE
# dS SE P-
value*
Associated epitopes 0.01062 0.00952 0.20969 0.07091 < 0.001
Non-associated epitopes 0.02387 0.02537 0.24220 0.12666 < 0.001
Not included epitopes 0.10532 0.01277 0.29085 0.04305 < 0.001
Non-epitopes 0.09793 0.01653 0.27329 0.04665 < 0.001
Average pairwise number of nonsynonymous (dN) and synonymous (dS)
substitutions per nonsynonymous and synonymous site, respectively,
estimated at different categories of epitope and non-epitope regions among
reference sequences of M group are given.
# Standard errors were estimated with 100 bootstrap replications in MEGA4.
* In pairwise t-tests, the null hypothesis of dS = dN was rejected in all four
comparisons.
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Page 10 of 16strategies for the epitope selection, which is one of the
most important steps in a multi-epitope vaccine design.
Some studies have suggested computer based epitope
prediction methods (e.g., [23,84-86]) for such selection,
although accuracy of in-silico methods for “prediction of
epitopes” is still debated [87]. It has been proposed that
a mixture of epitopes representing variable regions or
potential escape variants can be used to overcome enor-
mous viral diversity of HIV (e.g., [88,89]). Indeed, some
of the hypervariable regions have been shown to be
strongly immunogenic eliciting broad cross-subtype-spe-
cific responses [90,91]. On the other hand, such highly
variable regions may not account for critical functional
or structural features of the virus, while epitopes that
are highly conserved among different subtypes are likely
to be of functional significance and thus less prone to
escape mutations [28]. In either case, because of the
dynamic nature of intra-patient HIV evolution, the need
to achieve a broad immune response can be fulfilled
through multi-gene/multi-type approach [1,92], with
T-Helper activity playing an important role alongside
the CTL response (e.g., [93,94]).
Our results identified several association rules that not
only involved two epitope types and three genes, but also
were found in the vast majority of HIV-1 genomes ana-
lyzed. For instance, the association rule, GHQAAMQML
(CTL, Gag) - PKEPFRDYV (Th, Gag)-K L N W A S Q I Y
(CTL, Pol) - FLKEKGGL (CTL, Nef) (Figure 1) was pre-
sent in over 83.5% (818 sequences) of the worldwide HIV-
1 genomes analyzed. Among these, the epitope
GHQAAMQML is restricted by HLA alleles from differ-
ent supertypes, namely, B07 (B*38), B27 (B*1510, B*3901),
A02 (A*0201) and A03 (A*03) while epitopes PKEPFR-
DYV, KLNWASQIY and FLKEKGGL are recognized by
DQ5, A01 (A*3002) and B08 (B*0801) respectively. Nota-
bly, many of the associated epitopes harbor other epitopes
as sub-sequences that are restricted by yet other set of
HLA alleles, thus potentially expanding the breadth of epi-
tope recognition across a broad range of host HLA alleles.
For example, in the association rule involving epitopes
GLNKIVRMY (CTL, Gag) - PKEPFRDYV (Th, Gag)-
LVGKLNWASQIY (CTL, Pol) - FLKEKGGL (CTL, Nef),
epitope LVGKLNWASQIY includes another epitope,
KLNWASQIY, as its sub-sequence. These two epitopes
are recognized by alleles from different class I HLA loci,
B*1501 (B62) and A*3002 (A01), respectively. This not
only increases the potential for recognition population-
wide, but also increases the likelihood of this region being
recognized within the same individual. Moreover, recent
studies have shown promiscuous binding of CTL [95] and
Th epitopes [96] in HIV-1, i.e., epitope presentation and
T-cell recognition may occur in the context of alternative
HLA alleles different from the originally defined HLA
alleles. This further enhances potential population
coverage for recognition of the associated epitopes. It is
worth noting that the involvement of Ab epitopes in asso-
ciation rules described here was quite limited, partly
because of the strict presence/absence criteria used in the
initial selection of epitopes and association rule mining, as
well as the fact that the vast majority of Ab epitopes are
located within Env, a highly variable genomic region. Only
five association rules included a combination of Ab and
other epitope types (one Th-Ab, and four CTL-Ab asso-
ciations). Further, this study did not include conforma-
tional epitopes, which form a large number of HIV-1 B
cell epitopes. However, inclusion of a suitable Ab epitope
should be considered alongside the associated CTL and
Th epitopes, although further studies are needed to eluci-
date mechanisms of epitope association and interaction
across different types and to identify the most promising
Ab epitope candidates.
Although some individual epitopes have been previously
identified as conserved (Additional file 10), lack of uniform
criterion for defining conservation and use of different
subsets of HIV sequences (and often only few subtypes) in
different studies make it difficult to evaluate relative extent
of sequence conservation. Thus, our study provides first
comprehensive systematic survey of CTL, Th and Ab epi-
topes that are highly conserved and also co-occur together
among all subtypes of HIV-1. There are several advantages
of using multiple highly conserved epitopes from different
genomic locations, such as those represented by associa-
tion rules, in HIV vaccine. The highly conserved nature of
amino acid sequences of these epitopes, along with the sig-
nature of strong purifying selection acting at the nucleo-
tide level of the associated epitopes indicates that these
associated regions represent functionally critical genomic
regions, thus decreasing the likelihood of successful escape
mutations. The reasons behind such conservation remain
to be elucidated and may be driven by constraints acting
on the viral genome itself or restraints due to virus-host
interactions. It is likely that such persistently conserved
residues indeed comprise structurally or functionally
important elements critical for viral fitness, either due to
interactions between the associated regions, or due to
their involvement with the “outside” interactors. The latter
possibility is indirectly supported by the appearance of
compensatory mutations that accompany escape muta-
tions and that may be located elsewhere in the protein
sequence (e.g., [97,98]). Further, the structural constraints
may also be driven by interactions between regions har-
boring associated epitopes, direct or indirect. For example,
conserved 2T-3G epitopes SPRTLNAWV (CTL) and
GHQAAMQML (CTL) from the 5’ end of the Gag gene
are involved in formation of the secondary structure ele-
ments, such as helix I and IV, of the p24 capsid protein
[99]. Further, of 712 association rules that involve the for-
mer epitope, about 41.9% also include the latter epitope
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1 genome). Notably, helix I plays an important role in hex-
amerization of p24 during viral maturation [100] and
mutations in that portion of the capsid often give rise to
noninfectious viruses [99]. Likewise, the outside position-
ing of helix IV in the p24 hexameric ring as shown in Fig-
ure two of Li et al. (2000) [100] and PDB structure 3GV2
[101] suggests it may participate in protein-protein inter-
actions. It is possible that associated epitopes are involved
in RNA-protein interactions as well [102].
An additional advantage of using the associated epi-
topes is that even if escape mutations are successful at a
particular region, the other regions can still be targeted.
Moreover, because amino acid changes in these epitope
regions are relatively rare, inclusion of these regions in a
multi-epitope vaccine can not only provide protection
against a broad variety of existing HIV-1 variants
including many circulating recombinant forms, but can
also offer some protection against the new strains that
can arise in the near future. Most importantly, inclusion
of epitopes that are immuno-responsive to different
arms of the host immune machinery, such as CTL and
Th epitope combinations can enable stronger and more
efficient immune responses, similar to responses
achieved with adjuvant therapies (e.g., [45,48,49,103]).
Thus, our study provides a unique strategy to identify
suitable epitope candidates for multi-gene/multi-type vac-
cines that are both highly conserved across the global
HIV-1 population and highly likely to co-occur together in
the same viral genome in various HIV-1 subtypes and thus
can be simultaneously targeted by multi-epitope vaccines.
Some of these conserved epitopes have been included in
several recently tested vaccine candidates that showed pro-
mising results; however, none have included associated
epitopes from all three genes. For example, segments of
Gag, Pol and Nef were included in the recent LIPO-5 lipo-
peptide vaccine trial that showed T-cell responses in ~50%
of vaccines [104], yet it lacked associated epitopes from
Pol (Additional file 11). Further, because the included epi-
topes are already derived from the lists of epitopes with
experimentally demonstrated immunogenicity in humans,
(e.g., the list of “best defined” CTL epitopes by Frahm et
al., 2007 [56]), many challenges associated with the accu-
racy of computational epitope prediction (e.g.,
[87,105,106]) can be avoided. Moreover, while sequence
conservation does not assure that the epitope will be
strongly immunogenic (e.g., [107,108]), associated epitopes
reported in this study also exhibit a high degree of nucleo-
tide sequence conservation which is not readily identifiable
by other tools, such as Epitope Conservancy Analysis Tool
[107], making them suitable targets for other types of
treatments such as RNA interference [109].
Notably, a high degree of amino acid sequence conserva-
tion is not the only factor that influences identification of
epitopes as promising candidates. For example, several
epitopes included in the association rule mining, namely,
PIPIHYCAPA (Ab, Env), WASRELERF (CTL, Gag)a n d
RKAKIIRDY (CTL, Pol), were not involved in any of the
60626 associations that we discovered, showing that high
conservation at the amino acid level does not automati-
cally translate into involvement in association rules and
that other factors are also at play. While it is likely that
associated epitopes are harbored in functionally or structu-
rally important domains and thus experience strong con-
straints due to protein-protein or RNA-protein
interactions [102,110-116], further comprehensive experi-
mental and computational studies are needed to better
understand the functional and structural constraints and
mechanisms underlying the phenomenon of associated
epitopes and evolutionary forces that shape sequence
variability of these regions.
Conclusions
This study provides a comprehensive systematic survey of
CTL, Th and Ab epitopes that are both highly conserved
and co-occur together among all subtypes of HIV-1,
including circulating recombinant forms. Several co-
occurring epitope combinations were identified as potent
candidates for inclusion in multi-epitope vaccines,
including epitopes that are immuno-responsive to differ-
ent arms of the host immune machinery and can enable
stronger and more efficient immune responses, similar to
responses achieved with adjuvant therapies. Signature of
strong purifying selection acting at the nucleotide level of
the associated epitopes indicates that these regions are
functionally critical, although the exact reasons behind
such sequence conservation remain to be elucidated.
Additional material
Additional file 1: 90 HIV-1 reference sequences included in the
study. 90 HIV-1 reference sequences (as per 2007 subtype reference set
of the HIV Sequence database, Los Alamos National Laboratory) used for
the analysis of epitope presence.
Additional file 2: Epitopes included in the study. 606 epitopes used
in the analyses. Only epitopes shown to be immunogenic in human
were collected from the HIV Immunology database by Los Alamos
National Laboratory. Start and End refer to amino acid coordinates in
reference HXB2 genome.
Additional file 3: 888 non-reference sequences included in the
study. 888 non-reference sequences that represent global HIV-1
population (90 reference sequences are listed in Additional file 1).
Additional file 4: Number of unique association rules. Number of
unique association rules categorized based on the types of epitopes
involved in each association rule.
Additional file 5: 137 association rules involving epitopes from two
different types and three genes. 137 association rules involving
epitopes from 2 different types (CTL & Th) and three genes (Gag, Pol
&Nef). Each row separated by borders represents a single association rule
and each column represents a single non-overlapping genomic region.
Red letters denote CTL epitopes, green letters denote Th epitopes.
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Page 12 of 16Epitopes on blue background are those from Gag gene, while those in
tan and green backgrounds are from Pol and Nef genes, respectively.
Additional file 6: Subtype-wise frequencies of 137 2T-3G association
rules. Subtype-wise frequencies of 137 unique association rules where
epitopes from 3 genes and 2 types (2T-3G) are involved.
Additional file 7: Frequencies of 21 epitopes involved in 2T-3G
association rules. Frequencies of 21 epitopes involved in 2T-3G
association rules in different groups of HIV-1 sequences used in the
analysis
Additional file 8: Box-plot of dN and dS values at different
categories of epitopes and non-epitopes. Box-plot of dN and dS
values at different categories of epitopes and non-epitopes. P-values are
based on t-tests, comparing respective values among site categories.
Additional file 9: Plots of pairwise dN and dS values between
different genomic regions. Plots of pairwise dN and dS values between
(a) Associated epitope regions (b) Variable epitopes that were not
included in association rule mining and (c) Non-epitope regions for the
M group HIV-1 genome. Noticeably, there were no correlation between
dN and dS values from associated epitopes and respective dN and dS
values from non-epitope regions or variable epitopes. On the other
hand, dN and dS values were correlated between non-epitope regions
and variable epitopes.
Additional file 10: List of 41 associated epitopes and references to
published papers that reported epitopes as conserved and/or
evidence of escape. List of 41 associated epitopes and respective
references that have identified the epitope as conserved and/or provided
evidence of escape. It should be noted that the epitope conservation
criteria and sets of HIV-1 sequences used to define conserved epitopes
varied from study to study.
Additional file 11: List of associated epitopes and whether
canonical epitope sequences were included in the recently tested
vaccine candidates. List of associated epitopes and whether or not
canonical epitope sequences were included in several recently tested
vaccine candidates.
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